<div id="readability-page-1"><p>Bellevue Group AG raised its stake in shares of  PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 17.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 489,278 shares of the company's stock after purchasing an additional 74,355 shares during the quarter. Bellevue Group AG owned 0.88% of PROCEPT BioRobotics worth $28,182,000 as of its most recent filing with the Securities and Exchange Commission.</p><div><p><span></span><span>Get <strong>PROCEPT BioRobotics</strong> alerts:</span></p></div><ul><li>3 Underrated Robotics Stocks Poised for Huge Gains</li></ul><p>A number of other hedge funds have also modified their holdings of the stock. Mitsubishi UFJ Trust &amp; Banking Corp acquired a new position in  PROCEPT BioRobotics during the second quarter worth $5,892,000.  Lisanti Capital Growth LLC acquired a new stake in shares of  PROCEPT BioRobotics in the 2nd quarter valued at $2,532,000.  Osterweis Capital Management Inc. grew its holdings in shares of  PROCEPT BioRobotics by 98.0% in the 1st quarter. Osterweis Capital Management Inc. now owns 173,735 shares of the company's stock worth $10,122,000 after purchasing an additional 85,990 shares during the last quarter.  Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of  PROCEPT BioRobotics by 109.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,874 shares of the company's stock worth $9,209,000 after purchasing an additional 83,498 shares during the last quarter.  Finally, Candriam S.C.A. increased its position in shares of  PROCEPT BioRobotics by 104.8% during the 2nd quarter. Candriam S.C.A. now owns 63,125 shares of the company's stock worth $3,636,000 after purchasing an additional 32,301 shares in the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds. </p><h2>PROCEPT BioRobotics Price Performance</h2><p>PRCT opened at $35.99 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The stock has a market capitalization of $2.01 billion, a P/E ratio of -23.52 and a beta of 0.99. The company's 50 day simple moving average is $33.01 and its 200-day simple moving average is $43.59. PROCEPT BioRobotics Corporation has a one year low of $27.80 and a one year high of $92.92. </p><ul><li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li></ul><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. The firm had revenue of $83.33 million during the quarter, compared to analysts' expectations of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. PROCEPT BioRobotics's revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.40) EPS.  Sell-side analysts anticipate that  PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>PRCT has been the topic of a number of recent analyst reports. Piper Sandler  restated an &#34;overweight&#34; rating and issued a $50.00 price target (down from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Bank of America  reiterated a &#34;neutral&#34; rating and issued a $38.00 target price (down previously from $55.00) on shares of PROCEPT BioRobotics in a research note on Monday, December 8th. Jefferies Financial Group raised PROCEPT BioRobotics to a &#34;buy&#34; rating in a report on Friday. Leerink Partners  reaffirmed an &#34;outperform&#34; rating and set a $55.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Finally, Wells Fargo &amp; Company cut their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, November 5th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $53.70.</p><ul><li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li></ul><p><b>Read Our Latest Stock Analysis on PRCT</b></p><h2>PROCEPT BioRobotics Profile</h2> (Free Report)<p>PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).</p><h2>See Also</h2><ul><li>Five stocks we like better than PROCEPT BioRobotics</li><li>Canada Bond Market Holiday: How to Invest and Trade </li><li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li><li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li><li>The Best Holiday Present You Can Give Yourself? Costco Stock</li><li>Russell 2000 Index, How Investors Use it For Profitable Trading</li><li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li></ul><p><strong>Want to see what other hedge funds are holding PRCT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p><p>While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRCT

<p>Bellevue Group AG increased its stake in PROCEPT BioRobotics by 17.9% in Q2, acquiring 74,355 additional shares, now owning 0.88% of the company. The stock is valued at $28.18 million. Other investors also modified their holdings. PROCEPT BioRobotics reported a Q3 revenue increase of 42.6% year-over-year, with a negative net margin of 28.20%. Analysts have set a consensus price target of $53.70, with a "Moderate Buy" rating.</p>

Bellevue Group AG Acquires 74,355 Shares of PROCEPT BioRobotics Corporation $PRCT